Phase I/II dose-escalation trial of RGX-111 for the treatment of mucopolysaccharidosis type I
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs RGX 111 (Primary)
- Indications Mucopolysaccharidosis I
- Focus Adverse reactions; First in man
- 08 Nov 2017 According to a REGENXBIO media release, site activation is underway to support recruitment and patient enrollment, with the first patient expected to be dosed in the first half of 2018.
- 06 Jan 2017 According to a REGENXBIO media release, the company expects to begin enrollment in the study in the second half of 2017.
- 05 Jul 2016 According to Regenxbio media release, company expects to submit an IND of RGX-111 in the U.S. and Canada in the first half of 2017.